Latest Conference Articles

Explore how genomics, comorbidities, and patient goals steer frontline CLL therapy, from fixed-duration venetoclax regimens to continuous BTK inhibitors.

SEQUOIA subgroup shows zanubrutinib sustains 64% PFS at 6 years in CLL patients ≥80, with low early discontinuations and manageable safety.

Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims to shift induction therapy standards worldwide.

KOMET-007 insights show ziftomenib’s manageable toxicity, low QTc risk, and easy oral dosing, supporting long-term AML therapy and maintenance.

Ziftomenib plus 7+3 in newly diagnosed AML shows manageable safety and 90%+ deep responses with high MRD negativity and encouraging early survival in KOMET-007.

KOMET-007 data spotlight ziftomenib combos in newly diagnosed NPM1/KMT2A AML, detailing dosing, sequencing, and maintenance with 7+3 or aza/ven.

Early phase 2 results suggest 12-cycle pirtobrutinib–obinutuzumab yields high responses in untreated CLL with minimal cardiac effects.

Dr Haigentz breaks down 3 practice-changing ASCO 2026 lung cancer abstracts, from adjuvant targeted therapy to ADCs reshaping the immunotherapy backbone.

Andrew Spencer, MBBS, discusses how the inMMyCar trial is finding promise for in vivo CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Susan Bal, MD, discusses outcomes with arlo-cel, a GPRC5D-targeted CAR T product in relapsed/refractory multiple myeloma.

A scale combining frailty, chronological age, and comorbidities showed distinct outcomes among patients who received allogeneic hematopoietic cell transplant.

ASCO 2026 highlights breast cancer care: gene tests help skip chemo, new SERDs and ADCs improve outcomes, ctDNA guides earlier switches.

At the European Hematology Association Congress, researchers presented on novel treatments and combinations for newly diagnosed multiple myeloma, relapsed disease, and smoldering myeloma.

Johannes Schetelig, MD, MSc, discusses the importance of preventing life-threatening infections in light of research showing high nonrelapse mortality with PTCy.

Benjamin Herzberg, MD, highlights ASCO 2026's most exciting KRAS data, sequencing strategies, and emerging therapies for KRAS-mutant lung cancer.

Johannes Schetelig, MD, MSc, discusses findings on graft-vs-host disease prophylaxis in unrelated donor allogeneic stem cell transplants.

The phase 3 trial showed benefit with talquetamab/daratumumab with or without pomalidomide as early as the second line in myeloma.

EPCORE FL-1 data showed a consistent benefit with epcoritamab-based treatment in follicular lymphoma.

Erika Hamilton, MD, reviews the manageable safety profile of tucatinib plus HP maintenance therapy in HER2+ metastatic breast cancer from HER2CLIMB-05.

FBEM conditioning in ALL alloHSCT yields 92.1% 2-year OS and 14.3% relapse rate, with 0% 100-day NRM and manageable GVHD in 203 patients.

Real-world data show tarlatamab achieved 27.7% ORR and manageable toxicity in heavily pretreated patients with ES-SCLC with brain metastases at a single academic center.

In vivo anti-BCMA CAR T infusion shows favorable efficacy and safety with some patients beyond 9 months free of progression.

Dr Ajaz Khan of City of Hope shares key ASCO 2026 takeaways, including giredestrant, selpercatinib, ivonescimab, and the rise of ctDNA and AI in oncology.

Experts discuss their ASCO presentations on 3 rare disease states: uveal melanoma, mucosal melanoma, and Merkel cell carcinoma.

The phase 3 WU-KONG28 trial found that sunvozertinib decreased disease progression risk by 35% and nearly doubled response rates vs platinum-based chemotherapy in treatment-naive patients with NSCLC harboring EGFR exon 20 insertions.

Updated data from ASCO 2026 highlight advances in TNBC and HR+ breast cancer, including novel agents, biomarker strategies, and GLP-1 RA findings.

The combo did not, however, meet the coprimary end point of absolute change in total symptom score.

ANK-101, an IL-12 anchored immunotherapy, is being studied with checkpoint blockade in patients with non–small cell lung cancer in a phase 1b trial.

Switching early to camizestrant with a CDK4/6 inhibitor after ESR1 mutation detection extends progression-free outcomes in ER-positive breast cancer, despite FDA debate.

Phase 3 data show giredestrant plus palbociclib misses significant PFS gain vs letrozole, with similar safety, guiding future trials.